- May 30, 2022
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...
318
- May 25, 2022
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell...
127
- May 15, 2022
#COMY22 - Myeloma Abstracts - COMy World Congress Paris, France - May 12-15, 22
The 8th COMy World Congress – Paris, France & Online, May 12 - 15, 2022 #COMY 22 - MYELOMA ABSTRACTS The 8th COMy World Congress – Paris,...
278
- May 14, 2022
You are central to the care team: Be Empowered - IMF Patient & Family Webinar - May 14, 2022
IMF Patient & Family Webinar - New Frontiers In Myeloma Care, May 14, 2022 You are central to the care team: Be Empowered Watch Video on...
127
- May 13, 2022
The ESMO Virtual Plenaries - IKEMA Updated Analysis - Latest Data in Multiple Myeloma
The ESMO Virtual Plenaries The ESMO Virtual Plenaries - IKEMA Updated Analysis - Latest Data in Multiple Myeloma Learn more:...
58
- May 11, 2022
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480...
273
- May 8, 2022
International Academy for Clinical Hematology (IACH) Journal Club - May 17, 2022 - 07:00 PM Paris
International Academy for Clinical Hematology (IACH) Journal Club May 17, 2022 07:00 PM Paris Minimal Residual Disease After Autologous...
102
- May 6, 2022
PE: CDC Guidelines: How to prevent infections (Sepsis) while getting chemotherapy?
PE: CDC Guidelines - How to prevent infections (sepsis) while getting chemotherapy? Information for Patients and Caregivers | Preventing...
588